Metagenomi Therapeutics, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Metagenomi Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
44.8
52.3
25.2
Research and development
94.4
109
94.4
General and administrative
28.8
32
26.8
Operating expenses
123
141
121
Operating income
-78.5
-88.9
-96
Interest income
15.5
14.7
9.47
Other non-operating income
18.3
5.33
8.09
Pre-tax income
-60.2
-83.6
-87.9
Income tax
8.03
-5.51
-0.06
Net income
-68.3
-78.1
-87.9
EBITDA
-74.3
-83.5
-90.7
EPS, basic
-20.05
-2.36
-2.36
EPS, diluted
-20.05
-2.36
-2.36
Shares, basic (weighted)
3.4
33
37.3
Shares, diluted (weighted)
3.4
33
37.3
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
141
27.4
41.7
Short-term investments
131
221
119
Receivables
2.45
1.1
0.31
Other current assets
4.64
8.4
4.43
Total current assets
278
258
166
Property, plant and equipment
21.5
17.7
12.3
Lease right-of-use assets
43.6
39.9
35.1
Long-term investments
10.7
3.45
2.15
Other non-current assets
5.49
0.29
0.84
Total assets
365
325
221
Accounts payable
1.79
0.53
1.49
Deferred revenue
48.1
22.8
8.7
Total current liabilities
68.9
37.3
22.9
Lease liabilities
44.8
40.2
34.6
Other non-current liabilities
5.08
2.01
1.95
Total liabilities
150
89.7
62.5
Paid-in capital
9.46
457
469
Retained earnings
-145
-223
-311
Other comprehensive income
-0.1
0.71
0.26
Shareholders' equity
-136
235
159
Total equity
-136
235
159
Total liabilities and equity
365
325
221
Shares outstanding
3.4
37.4
37.6
Cash flow statement
FY2024
FY2024
FY2025
Net income
-68.3
-78.1
-87.9
Depreciation and amortization
4.21
5.41
5.32
Stock-based compensation
6.92
16.2
11.9
Change in receivables
-2.45
1.19
0.95
Change in payables
-0.08
-1.11
1.05
Cash from operations
-91.4
-109
-88.9
Capital expenditures
-9.81
-3.11
-0.57
Purchases of investments
-208
-306
-66.4
Sales and maturities of investments
264
221
170
Cash from investing
45.7
-88.2
104
Cash from financing
1.01
84
-0.36
Net change in cash
-44.7
-113
14.3
Free cash flow
-101
-112
-89.5
Income taxes paid
2.25
3.51
-2.24
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.15 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-83.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-53.8%
Net income / average total assets.
Return on invested capital (ROIC)
-108.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-51.8%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-32.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-31.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
12.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.50x
Current assets / current liabilities.
Quick ratio
4.37x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.37x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$2.28
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.27
Cash from operations / diluted weighted shares.
Book value per share
$2.98
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.39x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.39x
Market cap / tangible book value, when positive.
FCF yield
-197.5%
Free cash flow / market cap.
Earnings yield
-215.1%
Net income / market cap (the inverse of P/E).
What was Metagenomi Therapeutics, Inc.'s revenue in fiscal 2025?
Metagenomi Therapeutics, Inc. reported revenue of $25.2M for fiscal 2025, 51.8% lower than the year before.
Was Metagenomi Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $87.9M.
How much free cash flow did Metagenomi Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $88.9M minus capital expenditures of $574.0K left free cash flow of -$89.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.